Efficacy of 3 months of additional pioglitazone treatment in type 2 diabetes patients with alcoholic fatty liver disease

Metabolic dysfunction‐associated fatty liver disease directly related to liver fibrosis independent of insulin resistance, hyperlipidemia, and alcohol intake in morbidly obese patients

(2022) Susumu Inamine et al.   HEPATOLOGY RESEARCH

Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial

(2021) Giuseppe Della Pepa et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients

(2021) Jee-Fu Huang et al.   Hepatology International

Similarities and Differences: A Comparative Review of the Molecular Mechanisms and Effectors of NAFLD and AFLD

(2021) Pengyi Zhang et al.   Frontiers in Physiology

Reduced alcohol use in patients prescribed pioglitazone

(2021) Eric Dieperink et al.   AMERICAN JOURNAL ON ADDICTIONS

Causes of mortality in Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcohol related Fatty Liver Disease (AFLD).

(2020) Michael P Johnston et al.   CURRENT PHARMACEUTICAL DESIGN

MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease

(2020) Mohammed Eslam et al.   GASTROENTEROLOGY

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement

(2020) Mohammed Eslam et al.   JOURNAL OF HEPATOLOGY

What's in a name? Renaming ‘NAFLD’ to ‘MAFLD’

(2020) Yasser Fouad et al.   LIVER INTERNATIONAL

Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map

(2020) Jai Kumar et al.   DIGESTIVE AND LIVER DISEASE

Effect of alcohol consumption and the presence of fatty liver on the risk for incident type 2 diabetes: a population-based longitudinal study

(2020) Takuro Okamura et al.   BMJ Open Diabetes Research & Care

Hepatocellular carcinoma in the setting of alcohol-related liver disease

(2019) Nathalie Ganne-Carrié et al.   JOURNAL OF HEPATOLOGY

Alcohol Consumption and Risk of Liver Cirrhosis

(2019) Michael Roerecke et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial

(2018) Bancha Satirapoj et al.   PLoS One

Pioglitazone inhibits mitochondrial pyruvate metabolism and glucose production in hepatocytes

(2017) Christopher E. Shannon et al.   FEBS Journal

Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis

(2017) Giovanni Musso et al.   JAMA Internal Medicine

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus

(2016) Kenneth Cusi et al.   ANNALS OF INTERNAL MEDICINE

Pathogenesis of Alcoholic Liver Disease

(2016) Winston Dunn et al.   Clinics in Liver Disease

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

(2016) Zobair M. Younossi et al.   HEPATOLOGY

Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD)

(2016) Ratree Sawangjit et al.   MEDICINE

Alcohol drinking pattern and risk of alcoholic liver cirrhosis: A prospective cohort study

(2015) Gro Askgaard et al.   JOURNAL OF HEPATOLOGY

Hepatocellular carcinoma: clinical frontiers and perspectives

(2014) Jordi Bruix et al.   GUT

Report of the Japan Diabetes Society/Japanese Cancer Association joint committee on diabetes and cancer

(2013) Masato Kasuga et al.   CANCER SCIENCE

From NAFLD to NASH to cirrhosis—new insights into disease mechanisms

(2013) Alexander Wree et al.   Nature Reviews Gastroenterology & Hepatology

Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population

(2012) Yoshio Sumida et al.   BMC GASTROENTEROLOGY

Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: A pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study

(2012) Lauren N. Bell et al.   HEPATOLOGY

The epidemiology, pathogenesis and histopathology of fatty liver disease

(2012) Adam P Levene et al.   HISTOPATHOLOGY

Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis

(2011) E. Boettcher et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Activation of Nuclear PPARγ Receptors by the Antidiabetic Agent Pioglitazone Suppresses Alcohol Drinking and Relapse to Alcohol Seeking

(2011) Serena Stopponi et al.   BIOLOGICAL PSYCHIATRY

A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease

(2010) Giovanni Musso et al.   HEPATOLOGY

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

(2010) Arun J. Sanyal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multivariate analysis of risk factors for the development of type 2 diabetes in nonalcoholic fatty liver disease

(2009) Yasuji Arase et al.   JOURNAL OF GASTROENTEROLOGY

Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis

(2008) Guruprasad P. Aithal et al.   GASTROENTEROLOGY